|
|
||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Jean Mayer USDA Human Nutrition Research Center, Tufts University, Boston, MA (MY, SLB, ES, and PFJ), and the General Medicine Division and the Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA (JBM)
2 Supported by USDA agreement no. 58-1950-7-707, the Framingham Heart Study of the NIH-NHLBI (contract no. N01-HC-25195), a Career Development Award from the American Diabetes Association (to JBM), and NIDDK K24 DK080140 (to JBM). Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the US Department of Agriculture. 3 Reprints not available. Address correspondence to PF Jacques, USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, MA 02111. E-mail: paul.jacques{at}tufts.edug.
| ABSTRACT |
|---|
|
|
|---|
Objective: We aimed to examine associations between vitamin K intake and measures of insulin sensitivity and glycemic status in men and women aged 26–81 y.
Design: We assessed the cross-sectional associations of self-reported phylloquinone (vitamin K1) intake with insulin sensitivity and glycemic status in the Framingham Offspring Cohort. Dietary and supplemental phylloquinone intakes were assessed by using a food-frequency questionnaire. Insulin sensitivity was measured by fasting and 2-h post-oral-glucose-tolerance test (OGTT) insulin, the homeostasis model assessment of insulin resistance (HOMA-IR), and the insulin sensitivity index (ISI0,120). Glycemic status was assessed by fasting and 2-h post-OGTT glucose and glycated hemoglobin (HbA1c).
Results: Higher phylloquinone intake was associated with greater insulin sensitivity and glycemic status, as measured by 2-h post-OGTT insulin and glucose and ISI0,120, after adjustment for age, sex, waist circumference, lifestyle characteristics, and diet quality [2-h post-OGTT insulin: lowest and highest quintile, 81.0 and 72.7 µU/mL, respectively (P for trend = 0.003); 2-h post-OGTT glucose: 106.3 and 101.9 mg/dL, respectively (P for trend = 0.009); ISI0,120: 26.3 and 27.3 mgL2/mmolmUmin (P for trend = 0.009)]. Phylloquinone intake was not associated with fasting insulin and glucose concentrations, HOMA-IR, or HbA1c.
Conclusion: Our findings support a potential beneficial role for phylloquinone in glucose homeostasis in men and women.
| INTRODUCTION |
|---|
|
|
|---|
-carboxyglutamyl residues in certain proteins including the coagulation factors and the bone formation protein, osteocalcin. Data from the osteocalcin knockout mouse model suggest that osteocalcin may be involved in insulin sensitivity and insulin secretion (5). The role of vitamin K–dependent carboxylation of osteocalcin in glucose homeostasis is not known. Currently, there are no published data on the associations of phylloquinone intake with measures of insulin sensitivity and glycemic status in a community-based sample. We examined the cross-sectional associations between phylloquinone intake and both insulin sensitivity and glycemic status, as measured by fasting and 2-h post oral glucose tolerance test (OGTT) insulin and glucose concentrations, glycated hemoglobin (HbA1c), the homeostasis model assessment of insulin resistance (HOMA-IR), and the insulin sensitivity index (ISI0,120) in men and women who participated in the Framingham Offspring Study. We hypothesized that higher phylloquinone intake is associated with greater insulin sensitivity and improved glycemic status in men and women.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
All of the participants in the FOS provided written informed consent. The institutional review boards for human research at Boston University and the Tufts Medical Center approved this study.
Phylloquinone intake assessment
Usual dietary intakes for previous 12 mo were assessed by using a semiquantitative food-frequency questionnaire (FFQ), as described elsewhere (8). This FFQ was validated for various nutrients and foods (8, 9), including phylloquinone (10, 11). A significant correlation was observed between the phylloquinone intake calculated from this FFQ and that from three 4-d diet records (r = 0.53) (10). A biomarker-based validation study has shown plasma that phylloquinone concentrations increased approximately twofold in a linear fashion across phylloquinone intakes between 50 and 250 µg/d, as assessed by the FFQ (11).
The questionnaire was mailed to participants before their study examination, and the participants were asked to bring the completed questionnaire with them to their appointment. The FFQ consisted of a list of foods with a standard serving size and a selection of 9 frequency categories ranging from never or <1 serving/mo to >6 servings/d. Phylloquinone intake was calculated by multiplying the frequency of consumption of each unit of food from the FFQ by the phylloquinone contents of the specific portion. Separate questions about the use of vitamin and mineral supplements were also included in the FFQ. Phylloquinone intakes reported here included intakes both from diets and supplements. Data from the FFQ were considered reliable if reported total energy intakes were
600 kcal/d (2.51 MJ/d) for men and women but <4200 kcal/d (17.54 MJ/d) for men or <4000 kcal/d (16.74 MJ/d) for women, and if fewer than 13 items were left blank.
Insulin sensitivity measures
Fasting blood samples (
8 h) were collected at each examination cycle. Plasma and serum samples were stored at –70 °C. Plasma insulin concentrations were measured by using the Coat-A-Count 125I-radioimmunoassay (Diagnostic Products, Los Angeles, CA). This assay has cross-reactivity with proinsulin at the midcurve of 40%, intra-assay and interassay CVs of 5% to 10%, and a lower limit of sensitivity of 1.1 µU/mL (7.9 pmol/L). Plasma glucose concentrations were measured with a hexokinase regent kit (A-gent glucose test; Abbott Laboratories Inc, South Pasadena, CA). Glucose assays were performed in duplicate, and the CVs for this assay were <3%. The 75-g OGTT was administered, and the 2-h post-OGTT plasma insulin and glucose concentrations were measured. HbA1c was measured by using HPLC after an overnight dialysis against normal saline to remove the labile fraction. The interassay and intra-assay CVs were <2.5%. The assay was standardized against the HbA1c assay used in the Diabetes Control and Complication Trial (12).
We calculated 2 indexes of insulin sensitivity, HOMA-IR (13) and ISI0,120 (14). HOMA-IR is a surrogate measure of insulin sensitivity at basal state, and it tends to represent hepatic insulin sensitivity, whereas ISI0,120 reflects peripheral insulin resistance, glucose disposal, and β-cell response to an energy load (15). The HOMA-IR was calculated by using the following formula (13):
![]() | (1) |
![]() | (2) |
![]() | (3) |
![]() | (4) |
![]() | (5) |
Covariate information
Covariates used in these analyses were included because they were either determinants of insulin resistance and glycemic status, markers of a healthy (or unhealthy) lifestyle or diet quality, or other components of phylloquinone-containing foods. Covariates included age; sex; waist circumference; physical activity; cigarette smoking; alcohol consumption; estrogen use; multivitamin supplementation use; intakes of total energy, total fiber, potassium, saturated fatty acids, and n–3 fatty acids; and diet quality. Waist circumference was assessed at the level of the umbilicus while the participant was standing. Physical activity was determined as a metabolic equivalent–based score from a validated questionnaire of self-reported 24-h history of activity (16). We characterized cigarette smoking status as regularly smoking cigarettes in the past year (yes or no), multivitamin supplementation use as current use at the time of the examination (yes or no), and estrogen use as reported current use of oral conjugated estrogen at the time of the examination (yes or no). Intakes of total energy (kcal/d), alcohol (g/d), total fiber (g/d), potassium (mg/d), saturated fatty acids (g/d), and n–3 fatty acids (g/d) were assessed by using the semiquantitative FFQ (8). Overall diet quality was measured by using the 2005 Dietary Guidelines for Americans Adherence Index (DGAI), as described elsewhere (17).
Statistical analysis
We used SAS statistical software (version 9; SAS institute, Cary, NC) for all statistical analyses. Statistical significance was defined as P < 0.05. Normality of insulin sensitivity and glycemic status measures was tested. Because insulin concentrations and HOMA-IR were skewed to the right, we analyzed these variables with the natural logarithm transformation. Phylloquinone intake was categorized on the basis of quintiles of participants' intake levels. HbA1c was categorized into 2 groups (<6.5% and
6.5%) to capture participants with long-term hyperglycemia.
To describe subject characteristics across phylloquinone intake, analysis of covariance (ANCOVA) was performed. Age- and sex-adjusted means or percentages (95% CI) are presented.
To assess the association of phylloquinone intake with insulin sensitivity and glycemic status measures, we applied ANCOVA and logistic regression for continuous and dichotomous markers of insulin sensitivity and glycemic status, respectively. Phylloquinone intake is a potential surrogate marker for a healthy lifestyle and dietary pattern (18), which may relate to greater insulin sensitivity and improved glycemic status. As a result, lifestyle and diet quality potentially confound the association. Therefore, lifestyle characteristics were adjusted in model 1, and both lifestyle and dietary factors were controlled in model 2. Model 1 included age, sex, waist circumference, physical activity, cigarette smoking, alcohol consumption, estrogen use, and multivitamin supplementation use. Model 2 adjusted for total energy intake and diet quality measured by the DGAI in addition to covariates used in model 1. In addition, further adjustment for total fiber, saturated fatty acid, n–3 fatty acid, or potassium intake was performed. In all models, tests for trend by quintile category of phylloquinone intake were performed by assigning median values of phylloquinone intake for each quintile category and treating them as continuous variables. We presented least-squares means (95% CIs) and odds ratios (95% CIs) for results from ANCOVA and logistic regression analyses, respectively. We tested each association for interaction with age and sex; however, no interactions were significant.
| RESULTS |
|---|
|
|
|---|
|
|
| DISCUSSION |
|---|
|
|
|---|
Although phylloquinone intake was significantly associated with insulin sensitivity and glycemic status, as assessed from 2-h post-OGTT measurements in the present study, we did not find significant associations of phylloquinone intake with insulin sensitivity and glycemic status measures assessed in the fasting state. We currently do not have an explanation for the observed disparity in baseline and 2-h post-OGTT measures. However, our results are consistent with findings from a previous report from a small metabolic study of young men (2). Men with lower reported phylloquinone intake had lower insulin and higher glucose concentrations 30 min after oral glucose loading than did those with higher phylloquinone intake, but there was no association between phylloquinone intake and either fasting glucose or insulin concentrations (2). Potentially, delayed insulin release by the β-cells to oral glucose loading may explain observed elevation of 2-h post-OGTT insulin and glucose concentrations in persons with lower reported phylloquinone intake in the present study. However, our interpretation of data is limited because we did not assess the effect of phylloquinone intake on the acute insulin and glucose responses to oral glucose loading.
The nonsignificant association of phylloquinone intake with fasting insulin and HOMA-IR is potentially due to overadjustment in statistical models. Consumption of dark green vegetables, which are major sources of phylloquinone in this population, is part of the DGAI. When a subscore of the DGAI that did not include the dark green vegetable intake component was used instead of the overall DGAI in our statistical models, higher phylloquinone intake was associated with fasting insulin and HOMA-IR.
We also observed that higher phylloquinone intake was associated with higher ISI0,120, which indicates greater insulin sensitivity. ISI0,120 may capture more of the complexity of insulin resistance and glucose homeostasis than may either HOMA-IR or the individual measures of insulin and glucose concentrations. The ISI0,120 incorporates body weight and both fasting and 2-h post-OGTT insulin and glucose concentrations. It is a complex assessment of insulin sensitivity that accounts for β-cell response to glucose loading, peripheral and hepatic insulin sensitivity, and glucose disposal (15). A previous study has shown a high correlation between ISI0,120 and insulin sensitivity, as measured by the hyperinsulinemic-euglycemic clamp technique (14). In the absence of appropriate measures, the current study cannot determine whether phylloquinone intake is associated with β-cell response, insulin sensitivity, or glucose disposal (or all). However, all of these components are involved in glucose homeostasis, and their dysfunction contributes to diabetes (19, 20).
The potential biological mechanisms relating phylloquinone to insulin resistance and glucose homeostasis are not understood. Two forms of vitamin K, phylloquinone and menaquinone-4, are found in the pancreas (21). However, vitamin K–dependent proteins specific to the pancreas have not been identified. A recent study proposed that osteocalcin, one of the vitamin K–dependent proteins in the bone, may improve insulin sensitivity and increase β-cell functions, partially through the enhancement of adiponectin expression (5). Alternatively, it has been suggested that vitamin K has potential physiologic functions in addition to its classic role as a cofactor for
-carboxylation (22). In vivo, in vitro, and observational studies showed that vitamin K decreases inflammation-induced cytokines (23-25), so it is plausible that phylloquinone may improve insulin sensitivity and glycemic status by the suppression of inflammation.
The present study had several limitations. First, higher phylloquinone intake is a potential surrogate marker for a healthy dietary pattern, as characterized by higher intakes of fruit, vegetables, fish, and dietary fiber and lower intakes of saturated fat (18). Furthermore, because green leafy vegetables are also rich in other components (eg, dietary fiber and potassium) that have been reported to improve insulin sensitivity, phylloquinone intake may be only a marker for other components in green leafy vegetables that may be beneficial to insulin sensitivity and glycemic status. Although we cannot rule out the presence of residual confounding by overall lifestyle characteristics and diet quality (which may lead to the overestimation of the associations between phylloquinone intake and measures of insulin sensitivity and glycemic status), our finding does not support the hypothesis that these associations are due solely to diet quality. Additional adjustment for diet quality did not alter the significant associations between phylloquinone intake and measures of insulin sensitivity and glycemic status, as measured by ISI0,120 and by both 2-h post-OGTT insulin and glucose. Therefore, observed associations between phylloquinone intake and insulin sensitivity may indicate a biological role of phylloquinone in glucose homeostasis. A second limitation of the present study was its cross-sectional nature, which limited any causal inference from the observations. Finally, whereas most participants in the FOS have Northern European ancestry, the findings in the present study are consistent with those in Japanese young adults (2, 3). Thus, the similar findings in these 2 very distinct populations indicate that generalizability to other populations does not present a major limitation.
In summary, our findings suggest that phylloquinone intake may have a beneficial effect on glucose homeostasis, or it may serve as a surrogate marker of other dietary or lifestyle factors that were not controlled in the present analysis. These findings may lead to further areas of research that could help to elucidate potential novel functions of vitamin K. Future studies should focus on prospective relations between phylloquinone intakes and surrogate markers for insulin sensitivity, glycemic status, and type 2 diabetes, as well as on the putative biological mechanism explaining associations between phylloquinone and glucose homeostasis.
| ACKNOWLEDGMENTS |
|---|
The authors' responsibilities were as follows—MY: statistical analysis and draft of the manuscript; SLB: formulation of original idea, provision of the vitamin K data, and expertise in vitamin K; JBM: provision of insulin data and expertise in insulin resistance and diabetes; ES: expertise in insulin resistance and diabetes; PFJ: draft of the manuscript and expertise in epidemiology; and all authors: study design, interpretation of data, and critical revision of the manuscript. None of the authors had a personal or financial conflict of interest.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. C McCann and B. N Ames Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? Am. J. Clinical Nutrition, October 1, 2009; 90(4): 889 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yoshida, P. F. Jacques, J. B. Meigs, E. Saltzman, M. K. Shea, C. Gundberg, B. Dawson-Hughes, G. Dallal, and S. L. Booth Effect of Vitamin K Supplementation on Insulin Resistance in Older Men and Women Diabetes Care, November 1, 2008; 31(11): 2092 - 2096. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |